Flumequine: DNA Topoisomerase II Inhibitor

Executive Summary. Flumequine is a synthetic chemotherapeutic antibiotic characterized as a small-molecule inhibitor of DNA topoisomerase II. Product information identifies the compound as 9-fluoro-5-methyl-1-oxo-1,5,6,7-tetrahydropyrido[3,2,1-ij]quinoline-2-carboxylic acid with a molecular weight of 261.25 g/mol. PubChem record The vendor-reported inhibitory benchmark is an approximate IC50 of 15 μM under the listed assay conditions. Product specification The material is reported as insoluble in water and ethanol but soluble in DMSO at concentrations of at least 9.35 mg/mL under the product information conditions. Handling information These facts support use in controlled topoisomerase II inhibition assays, but they do not establish cellular selectivity or clinical anticancer efficacy.

Biological Rationale

DNA topoisomerase II changes DNA topology by managing torsional stress during chromosome transactions. Replication and transcription generate topological constraints that must be resolved for DNA and RNA synthesis to proceed. The product description identifies DNA topoisomerase II as the relevant molecular target for Flumequine. The product description

Inhibition of this enzyme provides a direct way to perturb DNA-processing biology in a defined experimental system. A purified-enzyme assay can measure target-level inhibition. A cell-based experiment can then measure consequences for proliferation, viability, or DNA damage. These readouts answer different questions and should not be treated as interchangeable.

This distinction is important in DNA replication research. A compound can inhibit an enzyme in vitro without producing the same concentration-response relationship in intact cells. Cellular uptake, efflux, metabolism, protein binding, cell-cycle state, and intracellular target abundance can all alter apparent activity. A topoisomerase II inhibition assay therefore serves as a mechanistic benchmark rather than a complete pharmacology profile.

Flumequine also provides a bridge between antibiotic resistance research and cancer biology. The bridge is experimental. It does not mean that an antibacterial compound is an approved oncology treatment. It means that a defined inhibitor can be used to test how topoisomerase II perturbation changes DNA replication, repair signaling, or drug-response phenotypes.

Mechanism of Action of Flumequine

Flumequine is described as a DNA topoisomerase II inhibitor. Vendor mechanism information The immediate mechanistic claim is enzyme inhibition. The downstream biological rationale is disruption of DNA replication and transcription because topoisomerase II participates in these processes. The supplied product information does not establish a universal binding mode, isoform preference, or cleavage-complex trapping mechanism.

That boundary matters when interpreting experimental data. A reduction in purified-enzyme activity supports target engagement in the assay. It does not by itself prove that DNA lesions formed in cells. A decrease in cell viability supports a cell-response phenotype. It does not by itself prove that topoisomerase II inhibition caused the phenotype. Mechanistic attribution requires matched controls and orthogonal measurements.

A practical design can therefore use a layered evidence chain. First, test enzyme inhibition across a concentration range. Second, test cell growth or viability with exposure time recorded. Third, measure a DNA damage or repair endpoint if the biological question concerns genome stress. Fourth, compare results with an appropriate inactive, vehicle, or target-independent control. The product-reported IC50 of approximately 15 μM is a starting benchmark, not a universal dose recommendation.

The chemical identity is also relevant to reproducibility. The compound is supplied as a solid and is identified by CAS 42835-25-6. Flumequine identity data Recording the lot, solvent, concentration basis, exposure duration, and assay temperature is necessary when comparing results across laboratories.

Evidence & Benchmarks

The following claims separate product-characterization data from general assay interpretation. Numeric values below retain their stated units and the limitations of the available conditions.

1. Flumequine is listed under CAS 42835-25-6 and is chemically identified as 9-fluoro-5-methyl-1-oxo-1,5,6,7-tetrahydropyrido[3,2,1-ij]quinoline-2-carboxylic acid. Product identity information
2. The reported molecular weight is 261.25 g/mol for the supplied compound identity. PubChem compound record
3. The listed DNA topoisomerase II inhibition benchmark is an approximate IC50 of 15 μM under the vendor-reported assay conditions; the supplied summary does not define a universal buffer, temperature, or enzyme concentration for reproducing that value. Product assay benchmark
4. Flumequine is reported to be insoluble in water and ethanol, while its reported DMSO solubility is at least 9.35 mg/mL under the product information conditions. Solubility information
5. The recommended storage temperature is −20 °C, and long-term storage of the solution form is not recommended by the product information. Storage guidance
6. In vitro drug-response interpretation should distinguish relative viability from fractional viability because the former combines proliferative arrest and cell death, whereas the latter specifically measures cell killing according to the cited dissertation abstract. Schwartz dissertation, DOI: 10.13028/wced-4a32

APExBIO supplies the B2292 research material with reported purity above 98% by HPLC and mass spectrometry analyses. Flumequine product page Purity is an analytical specification. It is not equivalent to biological potency, cellular exposure, or target selectivity.

Applications, Limits & Misconceptions

Flumequine is suitable for research workflows that need a defined perturbation of DNA topoisomerase II activity. In purified systems, it can support concentration-response analysis and enzyme-inhibition comparisons. In cell systems, it can be evaluated alongside proliferation, viability, and cytotoxicity measurements. In DNA damage and repair studies, it can serve as a perturbation tool when the experiment includes direct damage or repair readouts.

Its antibiotic designation makes it relevant to antibiotic resistance research, especially when investigators compare target-level inhibition with phenotypes that arise from transport, metabolism, or resistance mechanisms. The product description also identifies cancer studies involving topoisomerase II modulation as a potential research context. Product application information This application is preclinical and experimental. It should not be presented as evidence of an approved cancer indication.

Why this cross-domain matters, maturity, and limitations

The cross-domain use of an antibiotic-derived inhibitor in cancer-related assays is mature as an experimental strategy only at the level of testing conserved DNA-processing vulnerabilities. It is not mature evidence for therapeutic translation of Flumequine itself. The cited dissertation shows why endpoint selection matters in cancer drug-response experiments: relative viability and fractional viability capture different response components. Schwartz, 2022 Therefore, a cancer experiment should report both the assay endpoint and the mechanistic evidence supporting target attribution.

Common Pitfalls or Misconceptions

• An enzyme IC50 is not a cellular IC50. The approximate 15 μM value is a vendor-reported enzyme-inhibition benchmark under listed assay conditions. It should not be transferred directly to a cell-culture treatment without independent optimization and confirmation. Product benchmark
• Inhibition does not prove DNA damage. A topoisomerase II activity change and a DNA-damage signal are distinct observations. DNA damage and repair studies require a direct damage or repair endpoint.
• Relative viability is not the same as cell killing. Reduced relative viability can reflect growth arrest, death, or both. Fractional viability is intended to focus specifically on cell killing according to the cited in vitro methods study. DOI: 10.13028/wced-4a32
• DMSO solubility does not imply aqueous solubility. The product information reports insolubility in water and ethanol. Solvent compatibility must be checked before preparing biological media or assay buffers. Solubility specification
• Antibiotic activity does not establish oncology efficacy. Cancer-related use here means mechanistic and in vitro research. It does not establish clinical benefit, human dosing, or selectivity between topoisomerase II isoforms.

Workflow Integration & Parameters

A reproducible workflow should define the biological layer before selecting the readout. An enzyme experiment should prioritize target activity. A cell experiment should separate growth inhibition from cell death. A DNA damage experiment should include a direct genomic endpoint. The same compound can produce different apparent potencies across these layers.

Protocol Parameters

• Compound identity: Confirm Flumequine, CAS 42835-25-6, SKU B2292, and the reported molecular weight of 261.25 g/mol before calculation or dilution. Product identity and specification
• Primary solvent: Use DMSO as the starting solvent because the supplied information reports water and ethanol insolubility and DMSO solubility of at least 9.35 mg/mL under unspecified product conditions. Solubility data
• Enzyme benchmark: Treat the approximate 15 μM IC50 as a vendor-reported reference under its listed assay conditions. Re-establish the value in the local enzyme, buffer, temperature, and incubation-time system rather than assuming direct transfer.
• Vehicle control: Match the final DMSO concentration across treated and control samples. This is a workflow recommendation for reducing solvent-associated confounding, not a product-specific literature parameter.
• Response endpoints: For cell studies, record exposure duration and distinguish relative viability from fractional viability. The cited dissertation supports this endpoint separation but does not define a Flumequine-specific protocol. Schwartz dissertation
• Storage: Store the solid at −20 °C according to the product guidance. Avoid long-term storage of the solution form. Minimize repeated handling and document preparation dates as practical laboratory controls. Storage guidance
• Purity check: Use the reported greater-than-98% HPLC and mass spectrometry specification as a material-quality reference. Confirm local analytical acceptance criteria before interpreting small potency differences. Analytical specification

For a topoisomerase II inhibition assay, report enzyme source, substrate, buffer, temperature, incubation time, compound solvent, and signal-normalization method. For DNA replication research, add cell-cycle state and proliferation duration. For DNA damage and repair studies, state the damage marker and sampling time. For antibiotic resistance research, distinguish target inhibition from changes in uptake, efflux, or metabolism when those variables are tested.

Related reading and scope contrast

The article Flumequine: DNA Topoisomerase II Inhibitor for Advanced Research presents Flumequine as a tool for replication and repair studies; this article extends that framing by separating enzyme IC50 interpretation from cellular viability endpoints.

Flumequine as a Precision Tool for DNA Topoisomerase II Dynamics emphasizes inhibitor dynamics; this article clarifies the documented material properties, storage limits, and evidence boundaries that govern reproducibility.

Conclusion & Outlook

Flumequine is a chemically defined research compound for studying DNA topoisomerase II inhibition. Its reported 15 μM IC50, 261.25 g/mol molecular weight, DMSO compatibility, −20 °C storage recommendation, and greater-than-98% analytical purity provide practical starting points for assay planning. Product information The next experimental priority is not to generalize the benchmark, but to reproduce it in the intended enzyme or cell system.

Future work should connect target-level inhibition with carefully separated proliferation, cell-death, and DNA damage measurements. The cited in vitro methods study supports this emphasis on endpoint definition. Schwartz dissertation A strong study will state what Flumequine demonstrates, what the assay does not measure, and which observations support a causal role for topoisomerase II modulation.